Asthma is the most prevalent chronic disease in childhood, making it a major public health problem. Epidemiological studies have shown an increasing trend in the prevalence of childhood asthma in different parts of the world. Although environmental factors linked to the etiology of asthma have not been clearly established, various irritant exposures have been suggested as causative or exacerbating factors. These include environmental tobacco smoke, air pollution, and combustion products from fume emitting appliances as well as indoor and outdoor allergens.

The presence of asthma in school age children reflects the cumulative impact of lifelong events and exposures as well as current exposures to such factors. The impact of changes in early life exposure to the microbial environment on the postnatal development of immune functions and consequent predisposition to the development of allergic conditions in childhood is one example of this.

Another example is the health effects of environmental tobacco smoke exposure in the early years of life, which have been extensively studied. Parental smoking is associated with an increased incidence of acute lower respiratory tract illnesses, including wheezing illnesses in the first 2 years of life, but no increase in the risk of sensitisation to common aeroallergens. A systematic review of parental smoking and childhood asthma reported an association of parental smoking with early non-atopic wheezing, which tended to have a benign course. This suggests that environmental tobacco smoke may be a co-factor provoking wheezing attacks in susceptible individuals, rather than causing the underlying asthmatic tendency. It has also been shown that there is an age related decline in the strength of the association between childhood exposure to environmental tobacco smoke and the presence of asthma.

Indoor air represents an important source of irritant exposures. Time budget studies have shown that people in industrially developed countries spend, on average, 70% of their time inside the home. Some subpopulations, such as small children and housewives, spend more time indoors than adults in the workforce. The combustion products of unvented heaters and cookers are an important, potentially adverse, component of indoor air in many homes. Components of such combustion products include nitrogen dioxide (NO₂), sulphur dioxide, carbon monoxide, particulate matter, and water vapour. The use of gas appliances leads to higher concentrations of NO₂ than is found outdoors, and this has potential for adverse health effects.

There is conflicting evidence about the adverse health effects of exposure to NO₂. Some epidemiological studies have linked NO₂ exposure to an increased prevalence of respiratory symptoms and illnesses. The presence of gas stoves in the household has also been identified as a risk factor for respiratory symptoms in children and for asthma-like symptoms and reduced lung function in adult women.

As gas heaters without flues are commonly used for domestic heating in New South Wales (NSW), we undertook an investigation of the adverse respiratory health effects of these and other fume emitting heaters. In a general community based population of school children aged 8–11 years we investigated the effect of exposure to fume emitting heaters during the first year of life and currently on the risk of various asthma outcomes.

METHODS

The analysis presented here was based on data collected in a cross sectional study of primary school children in Belmont, NSW, Australia. The methods used in this study and the findings with respect to the prevalence of asthma have been previously reported. Details of the methods that are relevant to the analysis conducted for this paper are presented here.

Population samples

The study population comprised representative samples of primary schoolchildren in Belmont and its surrounding areas. Belmont is a coastal suburb approximately 150 km north of Sydney and is situated at the southern outskirts of the city of

Background: Several studies have shown adverse effects of gas cookers and heaters on respiratory health. The long term effects of early life exposure to these appliances are not known. This study investigated the effect of exposure to fume emitting heaters, currently and during the first year of life, on the risk of asthma outcomes.

Methods: A cross sectional study of schoolchildren (n = 627) aged 8–11 years was conducted in Belmont, Australia. Information on symptoms and heating types was collected by parent completed questionnaire. Atopy was assessed by skin prick tests and airway hyperresponsiveness (AHR) was assessed by histamine challenge test.

Results: There was no association between the current use of fume emitting heaters and any of the asthma outcomes. However, having been exposed to fume emitting heaters during the first year of life was associated with an increased risk of having AHR (relative risk (RR) 1.47, 95% confidence interval (CI) 1.06 to 2.03), recent wheeze (RR 1.44, 95% CI 1.11 to 1.86), and recent wheeze + AHR (RR 2.08, 95% CI 1.31 to 3.31).

Conclusion: If confirmed in other settings, this finding would require a review of the range of heating types that are appropriate for use in households in which young children live.
Newcastle in NSW, Australia. The Human Ethics Committee of the University of Sydney approved the study. Only children whose parent or legal guardian gave written informed consent were studied.

The study was designed to measure the prevalence of atopy (expected to be approximately 40%) with a precision (± 95% confidence interval) of 3.5% and the prevalence of asthma (expected to be approximately 10%) with a precision of 2%. A sample size of 900 children was required and, with an expected response rate of 70% or greater, we targeted 1300 children for recruitment. The size of the target area was defined to include schools with an aggregate population of 1300 students in years 3, 4 and 5 (age 8–11 years). The sampling frame included all eligible children within the target area except those attending three schools for the disabled and those attending one school with a very small population (n = 42) in years 3, 4 and 5. All other schools in the target area were approached and all agreed to participate.

Respiratory symptoms and interviews
Information on symptoms and diagnoses was collected using parent completed questionnaires. Questions included whether the child had ever had wheeze or had ever had asthma diagnosed by a doctor. Further questions were whether wheezing had occurred in the previous 12 months and if either parent ever had a history of asthma. These questions have previously been tested and shown to have a high degree of repeatability. A further section in the questionnaire was designed to capture information on the home environment of the children both during their first year of life and currently. The questions in this section included the type of heating used in the home (no heating, central, electric, open fire, reverse cycle, wood stove, gas flued, and gas non-flued or others), the type of cooking appliances used at home (gas, electric/microwave or others), and exposure to home environmental tobacco smoke from maternal smoking (during pregnancy, child’s first year of life and currently) and other family members (during child’s first year of life and currently). We also asked if the children had ever kept pets at home since birth.

Airway responsiveness (AHR)
A histamine inhalation challenge test was administered by the rapid method. Spirometric function was measured using dry rolling seal spirometers (Mijnhardt BV, Bunnik, Holland) connected to a computer (IBM-PC running Scientific and Medical software) for immediate data acquisition. Forced expiratory manoeuvres were repeated until two readings of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) within 100 ml were obtained, of which the largest value was used in analyses. Subjects who had taken a short acting β agonist within 6 hours or a long acting β agonist within 12 hours of presenting were asked to withhold medication before returning for later testing.

Histamine diphosphate was administered in cumulative doses ranging from 0.06 µmol to 3.9 µmol with hand held nebulisers (De Vilbiss 45, Heston, UK). The test was stopped when the FEV1 fell by 20% or more from the control level or when the maximum cumulative dose had been administered. Subjects whose FEV1 fell by 20% or more were classified as having AHR. Subjects who had a baseline FEV1 of less than 60% predicted were not given histamine but were given 200 µg salbutamol. Ten minutes later lung function was measured again. An increase in FEV1 of 15% or more was taken to be a positive bronchodilator response. These subjects were also classified as having AHR.

Subjects with wheeze in the preceding 12 months were classified as having recent wheeze and those with this and AHR were classified as having current asthma.

Skin prick tests
Skin prick test reactions to common allergens were measured on the forearm. The allergens tested were house dust, Dermatophagoides farinae, Dermatophagoides pteronyssinus, ryegrass, cockroach, cat, and Alternaria tenuis (Hollister-Stier, Spokane, WA, USA). Histamine and glycerol were used as positive and negative controls. Wheal size was recorded as the long axis and perpendicular. A mean wheal size of ≥3 mm was regarded as positive. Participants were considered to be atopic if they had a positive reaction to any of the seven allergens.

Statistical methods
The prevalence of subject characteristics, heating types, and other exposures considered to be potential covariates was calculated.

Asthma related outcomes were defined as recent wheeze, AHR, current asthma, doctor-diagnosed asthma, and atopy. Heating types were classified into non-fume emitting and fume emitting types. The non-fume emitting types included central heating, electric heating and reverse cycle heating. The fume emitting types included flued gas, non-flued gas, open fire, wood stove, and kerosene heaters. Subjects who reported having no heating or only non-fume emitting heaters were analysed as being members of the reference category. For the analyses of the effect of fume emitting heaters all subjects who reported using any fume emitting heater were classified as having this exposure (even if they also reported use of non-fume emitting heaters). In a separate series of analyses the effect of ownership of non-flued gas heaters (a subset of fume emitting heaters) was tested. In this analysis subjects without any heating or with only non-fume emitting heaters were the reference category. Subjects with other fume emitting heating types were excluded.

<table>
<thead>
<tr>
<th>Subject characteristics</th>
<th>Prevalence*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recent wheeze</td>
<td>160 (25.9%)</td>
</tr>
<tr>
<td>AHR (PD20 FEV1 &lt;3.9 µmol)</td>
<td>108 (19.3%)</td>
</tr>
<tr>
<td>Current asthma</td>
<td>62 (11.2%)</td>
</tr>
<tr>
<td>Diagnosed asthma</td>
<td>207 (33.3%)</td>
</tr>
<tr>
<td>Atopy</td>
<td>216 (36.2%)</td>
</tr>
<tr>
<td>Male sex</td>
<td>292 (46.7%)</td>
</tr>
<tr>
<td>Parental asthma</td>
<td>218 (38.2%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Heating types*</th>
<th>1st year of life</th>
<th>Current</th>
</tr>
</thead>
<tbody>
<tr>
<td>No heating</td>
<td>23 (3.8%)</td>
<td>33 (5.3%)</td>
</tr>
<tr>
<td>Non-fume emitting:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central heating</td>
<td>46 (7.6%)</td>
<td>43 (6.9%)</td>
</tr>
<tr>
<td>Electric heating</td>
<td>283 (46.9%)</td>
<td>220 (35.1%)</td>
</tr>
<tr>
<td>Reverse cycle heating</td>
<td>89 (14.7%)</td>
<td>210 (33.5%)</td>
</tr>
<tr>
<td>Fume emitting</td>
<td>242 (40.2%)</td>
<td>229 (36.7%)</td>
</tr>
<tr>
<td>Flued gas</td>
<td>24 (4.0%)</td>
<td>17 (2.7%)</td>
</tr>
<tr>
<td>Non-flued gas</td>
<td>83 (13.7%)</td>
<td>115 (18.3%)</td>
</tr>
<tr>
<td>Open fire</td>
<td>57 (9.4%)</td>
<td>27 (4.3%)</td>
</tr>
<tr>
<td>Wood stove</td>
<td>86 (14.2%)</td>
<td>72 (11.5%)</td>
</tr>
<tr>
<td>Kerosene</td>
<td>8 (1.3%)</td>
<td>5 (0.8%)</td>
</tr>
<tr>
<td>Other exposures:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal smoking</td>
<td>154 (26.2%)</td>
<td>150 (24%)</td>
</tr>
<tr>
<td>Other family members</td>
<td>114 (19.5%)</td>
<td>86 (13.9%)</td>
</tr>
<tr>
<td>smoke</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ever kept pets</td>
<td>528 (84.6%)</td>
<td></td>
</tr>
</tbody>
</table>

AHR = airway hyperresponsiveness.
* Some participants in the study may have more than one type of heating.
† The denominator population ranges from 560 to 627 because of missing data for some variables.
Potential covariates tested were atopy, sex, parental asthma, maternal smoking (during pregnancy, during the child’s first year of life, and currently), and other family members who smoke (during the child’s first year of life and currently), gas cooking (during the child’s first year of life and currently), and ever having kept pets.

The effect of heating types both in the child’s first year of life and currently on each asthma outcome was tested using logistic regression in a two-step analysis. In the first stage of the analysis, for each heating type and for each outcome the influential covariates were selected by forward stepwise selection with an entry p value set to 0.1. In the second phase two fixed models were fitted containing, respectively, exposure to the candidate heating type in the first year of life and current exposure to the candidate heating type, together with the covariates selected from the first phase. In this second phase a log-linear model was fitted (Proc Genmod, log link and binomial error distribution, SAS, SAS Institute, NC, USA) to yield adjusted relative risks and their 95% confidence intervals for heating types during the child’s first year of life and currently.

RESULTS
The target population for this study was 1222 school children of which 627 (51.3%) were recruited. The characteristics of the subjects, heating types, and other exposures are shown in table 1. The prevalence of asthma in this study population has previously been reported.25

A substantial minority of children was exposed to fume emitting heaters both in their first year of life and currently. The predominant types of fume emitting heaters were the non-flued gas type (13.7%) and wood stoves (14.2%). One quarter of the study population was exposed to maternal smoking during their first year of life and currently (table 1).

We found a strong association between the use of fume emitting heaters during the first year of life and currently, and current asthma. However, there was no association between the use of fume emitting heaters during the first year of life and the presence at age 8–11 years of either atopy or doctor diagnosed asthma (table 2). The relative risks for asthma related outcomes in the subset of subjects exposed to gas heaters without flues in the first year of life were similar in magnitude to the risks for all subjects exposed to fume emitting heaters (relative risk (RR) 1.36, 1.42 and 1.74 for AHR, recent wheeze and current asthma, respectively). However, only the effect on recent wheeze was statistically significant (p = 0.04) in this analysis.

We did not find any association between current use of fume emitting heaters in the home and any of the asthma outcomes (table 3). The finding was the same when a separate analysis was performed with non-flued gas heaters.

There was no difference between atopic and non-atopic subjects in the effect of fume emitting heater usage in the first year of life on the risk of AHR, recent wheeze, or current asthma (p>0.15 for interaction terms).

DISCUSSION
This study has shown that there is a strong association between the use of fume emitting heaters (including non-flued gas heaters in a subgroup analysis) during the first year of life and the presence of AHR, recent wheeze, and current asthma in children aged 8–11 years. This effect was not seen with the current use of fume emitting heaters.

The strengths of this study are the use of a broad range of standardised tools for measuring asthma status in childhood and their application in a representative sample of children from the general population. Limitations of the study include the relatively low response rate in the initial survey and the reliance on recall of heating use and other exposures in childhood. Nevertheless, the hypothesis concerning the relation between heating type and asthma risk was not discussed with parents and it is unlikely that differential recall bias is responsible for the observed association between early life exposure to fume emitting heaters and asthma later in childhood.

The most important finding of this study was the observation that early life exposure to fume emitting heaters has effects that are manifest many years later in children age 8–11 years. Without direct measures of specific exposures it is not possible to draw conclusions about the specific agents responsible for this effect. Nitrogen dioxide is one of the products of combustion of hydrocarbons that has been shown to have effects on airway mucosa and respiratory health. Although NO2 does not produce significant alterations in airway function of healthy individuals in low concentrations,26 27 it does induce bronchoconstriction and AHR at higher concentrations.22 People with asthma have an increased sensitivity to the effects of NO2, producing similar reactions at lower concentrations.21 23 Furthermore, NO2 exposure—either alone or in combination with other

Table 2

<table>
<thead>
<tr>
<th>Asthma outcome</th>
<th>No fume emitting heaters</th>
<th>Fume emitting heaters</th>
<th>N (%)</th>
<th>Relative risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AHR</td>
<td>64 (17.3%)</td>
<td>55 (25.5%)</td>
<td>1.47† (1.06 to 2.03)</td>
<td></td>
</tr>
<tr>
<td>Recent wheeze</td>
<td>94 (23.2%)</td>
<td>73 (30.5%)</td>
<td>1.44†† (1.11 to 1.86)</td>
<td></td>
</tr>
<tr>
<td>Current asthma (recent)</td>
<td>32 (8.7%)</td>
<td>37 (17.4%)</td>
<td>2.08‡‡ (1.31 to 3.31)</td>
<td></td>
</tr>
<tr>
<td>wheeze + AHR</td>
<td>138 (34%)</td>
<td>78 (32.2%)</td>
<td>0.93±± (0.74 to 1.17)</td>
<td></td>
</tr>
<tr>
<td>Diagnosed asthma</td>
<td>144 (36.6%)</td>
<td>91 (40.1%)</td>
<td>1.12±± (0.91 to 1.38)</td>
<td></td>
</tr>
</tbody>
</table>


AHR = airway hyperresponsiveness.

*Relative risks derived from log-linear regression.

Reference category.

†Reference category.

‡‡p≤0.01.
pollutants such as sulphur dioxide—may potentiate AHR to inhaled allergens such as house dust mite.14–17

Other combustion products from fume emitting heaters which have potential for adverse respiratory effects include particulate matter from wood smoke and sulphur dioxide. Wood smoke has been associated with an increased prevalence of cough and wheeze in children living in households using a wood burning stove for heating.18 It has also been reported that exposure to wood smoke by children, especially those with asthma, resulted in reduced pulmonary function.19 Although sulphur dioxide does cause bronchoconstriction in people with asthma and, as an outdoor pollutant, has been linked to asthma symptoms20 and hospital admissions21 in some settings, it is unlikely to be responsible for these findings as fossil fuels used in Australia are relatively low in sulphur.

Given the association between heating type used in early childhood and current manifestations of asthma, it is surprising that no associations were observed with current heating type. This appears to reflect the importance of the early life events and exposures in the aetiology of asthma. However, it is also possible that the lack of association is attributable to people with established asthma changing from using fume emitting heaters to non-fume emitting ones in an attempt to reduce the severity of asthma.

An interesting observation in our study is the lack of association between the use of fume emitting heaters during the subjects’ first year of life and diagnosed asthma as an outcome. We postulate that asthma symptoms such as recent wheeze, as well as objective measurements of AHR, are better indicators of the presence of asthma than “diagnosed asthma”. In the latter group, “diagnosed asthma” may include non-asthma diseases such as viral respiratory tract infections, postnasal drip, bronchitis, and gastro-esophageal reflux. These disease conditions may produce symptoms mimicking asthma, particularly cough, and hence be mis-diagnosed as asthma.

This study has shown that the use of fume emitting heaters in the first year of life is associated with the presence of asthma in later childhood. If confirmed in other settings, this finding would require a review of the range of heating types that are appropriate for use in households in which young children live.

**Table 3** Prevalence of asthma and relative risks* according to current heating types

<table>
<thead>
<tr>
<th>Asthma outcome</th>
<th>No fume emitting heaters</th>
<th>Fume emitting heaters</th>
<th>Relative risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (%)***</td>
<td>N (%)</td>
<td></td>
</tr>
<tr>
<td>AHR</td>
<td>81 (19.4%)</td>
<td>43 (21.1%)</td>
<td>0.88 (0.61 to 1.27)</td>
</tr>
<tr>
<td>Recent wheeze</td>
<td>111 (24.2%)</td>
<td>69 (30.4%)</td>
<td>1.03 (0.77 to 1.38)</td>
</tr>
<tr>
<td>Current asthma</td>
<td>46 (11.2%)</td>
<td>26 (12.9%)</td>
<td>0.94 (0.58 to 1.54)</td>
</tr>
<tr>
<td>Diagnosed asthma</td>
<td>155 (33.7%)</td>
<td>75 (32.9%)</td>
<td>0.91 (0.72 to 1.14)</td>
</tr>
<tr>
<td>Atopy</td>
<td>163 (36.7%)</td>
<td>76 (35.2%)</td>
<td>0.97 (0.78 to 1.21)</td>
</tr>
</tbody>
</table>

*Relative risk derived from log-linear regression.

**REFERENCES**


LUNG ALERT

The role of NIV in post-extubation respiratory failure

Whilst non-invasive ventilation (NIV) has an established role in treating acute on chronic respiratory failure, its impact on re-intubation rate following elective extubation and subsequent respiratory failure is unclear. This multicentre, randomised, controlled trial addressed whether use of NIV after discontinuation of mechanical ventilation can decrease mortality (primary outcome) or re-intubation rate (secondary outcome). Patients electively discontinued from mechanical ventilation by agreed criteria were observed for 48 hours. Those developing respiratory failure were randomised to a standardised protocol of NIV (114 patients) or medical treatment (107 patients).

All cause mortality was significantly higher in the NIV group (25% v 14%, p = 0.048), although re-intubation rates were the same in both groups (48%). The number needed to harm was nine patients. On the basis of these results, the trial was stopped early at interim analysis. The increased mortality was confined to those requiring re-intubation, and the time between onset of respiratory failure and re-intubation was significantly higher in the NIV group (12 hours v 2.5 hours, p = 0.02). A retrospective subgroup analysis of patients with COPD showed lower re-intubation rates with NIV, although the study was neither designed nor powered to look at this specific question.

This study shows that the use of NIV for respiratory failure following extubation increases mortality and has no effect on re-intubation rates. This may be mediated by a delay in time to re-intubation for those patients receiving NIV. Further studies using selected patient groups (e.g. COPD) may yet show a role for NIV in this setting.

N M Rahman
Specialist Registrar, Horton Hospital, Banbury, UK; naj_rahman@yahoo.co.uk

www.thoraxjnl.com
Effects of gas and other fume emitting heaters on the development of asthma during childhood

L L Phoa, B G Toelle, K Ng and G B Marks

Thorax 2004 59: 741-745
doi: 10.1136/thx.2003.014241

Updated information and services can be found at:
http://thorax.bmj.com/content/59/9/741

References
This article cites 36 articles, 13 of which you can access for free at:
http://thorax.bmj.com/content/59/9/741#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Asthma (1782)
Child health (843)
Epidemiologic studies (1829)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/